EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting P2RY2 reprograms tumor immunity and inhibits tumor growth in non-small cell lung cancer

Ahmed El-Gazzar, Bertram Aschenbrenner, Agnes Forsthuber, Markus Kramer, Zahra Kargarpour, Seda Metekol, Lisa John, Anastasia Papaporfyriou, Maša Bereš, Sarah Trouvilliez, Monika Homolya, Balázs Döme und 13 weitere

Cancer Letters · 2026-06 · 647 · 218448

DOI: 10.1016/j.canlet.2026.218448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-06. Verfasst von Ahmed El-Gazzar und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonology, Department of Internal Medicine II, Comprehensive Center for Chest Diseases, Medical University of Vienna, Vienna, Austria. …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Receptors, Purinergic P2Y2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund, Magyar Tudományos Akadémia, Medizinische Universität Wien.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The enrichment of immunosuppressive M2 macrophages, combined with diminished CD8+ T cell infiltration, represents a key mechanism driving tumor progression and limiting immunotherapy efficacy in non-small cell lung cancer (NSCLC). Here, we provide evidence that the purinergic P2Y2 receptor (P2RY2) is a key regulator of M2 macrophage enrichment and contributes to the exclusion of CD8+ T cells from the tumor microenvironment (TME). P2RY2 expression is significantly elevated in human NSCLC compared to non-malignant tissues and M2-like macrophages expressing P2RY2 are more prevalent in tumors with an advanced TNM (Tumor, Node, Metastasis) stage. Elevated P2RY2 mRNA levels are significantly associated with poorer overall survival in a NSCLC patients. Furthermore, we selectively inhibited P2RY2 in syngeneic or autochthonous mouse models of NSCLC driven by Kras or Egfr mutations. This resulted in a significant reduction of M2-like macrophages, enhanced CD8+ T cell migration and tumor infiltration and a marked decrease in tumor burden. Similar results were evident following the genetic deletion of P2ry2, validating the impact on the TME. Importantly, macrophages are the predominant P2RY2-expressing cells within the TME. Moreover, tumor-educated macrophages (TEMs) isolated from P2ry2-/- tumor-bearing mice exhibited reduced proliferation compared with wild-type macrophages when co-cultured with LLC1 cells, revealing a potential mechanism underlying P2RY2-mediated pro-tumorigenic activity. Our study underscores the clinical significance of P2RY2 in NSCLC and provides evidence of its pivotal role in the regulation of M2 macrophage enrichment and the exclusion of CD8+ T cells from the TME. Targeting P2RY2 may offer a novel immunotherapeutic intervention for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsReceptors, Purinergic P2Y2AnimalsHumansCD8-Positive T-LymphocytesTumor MicroenvironmentCell ProliferationMacrophagesMiceCell Line, TumorFemaleCell MovementLymphocytes, Tumor-InfiltratingMice, Inbred C57BL

Stichwörter der Autor:innen

Cytotoxic CD8(+) T cellsM2-like macrophagesNon-small cell lung cancerP2RY2Purinergic receptors

Substanzen

Receptors, Purinergic P2Y2P2RY2 protein, human

Autor:innen und Institutionen

  • Division of Pulmonology, Department of Internal Medicine II, Comprehensive Center for Chest Diseases, Medical University of Vienna, Vienna, Austria. Electronic address: ahmed.el-gazzar@meduniwien.ac.at.
  • Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Division of Pulmonology, Department of Internal Medicine II, Comprehensive Center for Chest Diseases, Medical University of Vienna, Vienna, Austria.
  • Division of Pulmonology, Department of Internal Medicine II, Comprehensive Center for Chest Diseases, Medical University of Vienna, Vienna, Austria; Department of Biosciences and Medical Biology, Paris-Lodron University…
  • Institute of Pharmacology, Center of Physiology and Pharmacology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Translational Thoracic Oncology Laboratory, Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Translational Medicine, Lund University, Lund, Sweden…

Förderung

  • Austrian Science Fund
  • Magyar Tudományos Akadémia
  • Medizinische Universität Wien
  • City of Vienna
  • International Association for the Study of Lung Cancer
  • Österreichische Akademie der Wissenschaften
  • Innovációs és Technológiai Minisztérium
  • Nemzeti Kutatási Fejlesztési és Innovációs Hivatal

Zitieren

APA

El-Gazzar, A., Aschenbrenner, B., Forsthuber, A., Kramer, M., Kargarpour, Z., Metekol, S., John, L., Papaporfyriou, A., Bereš, M., Trouvilliez, S., Homolya, M., Döme, B., Megyesfalvi, Z., Horvath, L., Lang, C., Hoda, M. A., Zeillinger, R., Obermayr, E., Geleff, S., …, & Idzko, M. (2026). Targeting P2RY2 reprograms tumor immunity and inhibits tumor growth in non-small cell lung cancer. Cancer Letters, 647, 218448. https://doi.org/10.1016/j.canlet.2026.218448

Vancouver

El-Gazzar A, Aschenbrenner B, Forsthuber A, Kramer M, Kargarpour Z, Metekol S, et al. Targeting P2RY2 reprograms tumor immunity and inhibits tumor growth in non-small cell lung cancer. Cancer Letters. 2026;647:218448. doi:10.1016/j.canlet.2026.218448

BibTeX
@article{ElGazzar2026,
  author = {El-Gazzar, Ahmed and Aschenbrenner, Bertram and Forsthuber, Agnes and Kramer, Markus and Kargarpour, Zahra and Metekol, Seda and John, Lisa and Papaporfyriou, Anastasia and Bereš, Maša and Trouvilliez, Sarah and Homolya, Monika and Döme, Balázs and Megyesfalvi, Zsolt and Horvath, Lilla and Lang, Christian and Hoda, Mir Alireza and Zeillinger, Robert and Obermayr, Eva and Geleff, Silvana and Frommlet, Florian and Lichtenberger, Beate M and Gompelmann, Daniela and Casanova, Emilio and Moll, Herwig P and Idzko, Marco},
  title = {Targeting P2RY2 reprograms tumor immunity and inhibits tumor growth in non-small cell lung cancer},
  journal = {Cancer Letters},
  year = {2026},
  volume = {647},
  pages = {218448},
  doi = {10.1016/j.canlet.2026.218448}
}
Kostenlos starten →